Showing 1 - 7 results of 7 for search 'Elias Drakos', query time: 0.03s Refine Results
  1. 1
    P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)

    P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL) by Ioanna Xagoraris, Konstantina Stathopoulou, Persa Xyderou, Marzia Palma, Elias Drakos, Theodoros P. Vassilakopoulos, Georgios Z. Rassidakis

    Published 2022-10-01
    Get full text
    Article
  2. 2
    P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)

    P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL) by Ioanna Xagoraris, Konstantina Stathopoulou, Stefanie Renken, Andreas Lundqvist, Francois Xavier Claret, Elias Drakos, Georgios Z. Rassidakis

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Promyelocytic leukemia protein regulates angiogenesis and epithelial–mesenchymal transition to limit metastasis in MDA‐MB‐231 breast cancer cells

    Promyelocytic leukemia protein regulates angiogenesis and epithelial–mesenchymal transition to limit metastasis in MDA‐MB‐231 breast cancer cells by Amalia P. Vogiatzoglou, Syrago Spanou, Nikoleta Sachini, Elias Drakos, Christoforos Nikolaou, Takis Makatounakis, Androniki Kretsovali, Joseph Papamatheakis

    Published 2023-10-01
    Get full text
    Article
  4. 4
    Case report: a rare case of diffusely metastatic BRAF V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid gland

    Case report: a rare case of diffusely metastatic BRAF V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid gland by Aristeidis E. Boukouris, Ioannis Kokkinakis, Elias Drakos, Maria Sfakianaki, Maria Tzardi, Dimitrios Mavroudis, Dimitrios Mavroudis, John Souglakos, John Souglakos

    Published 2025-01-01
    Get full text
    Article
  5. 5
    The Temozolomide–Doxorubicin paradox in Glioblastoma in vitro–in silico preclinical drug-screening

    The Temozolomide–Doxorubicin paradox in Glioblastoma in vitro–in silico preclinical drug-screening by Mariam-Eleni Oraiopoulou, Eleftheria Tzamali, Stylianos E. Psycharakis, Georgios Tzedakis, Takis Makatounakis, Katina Manolitsi, Elias Drakos, Antonis F. Vakis, Giannis Zacharakis, Joseph Papamatheakis, Vangelis Sakkalis

    Published 2024-02-01
    Get full text
    Article
  6. 6
    ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells

    ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells by Amineh Ghaderi, Amir Hossein Daneshmanesh, Ali Moshfegh, Parviz Kokhaei, Jan Vågberg, Johan Schultz, Thomas Olin, Sara Harrysson, Karin E Smedby, Elias Drakos, Georgios Z. Rassidakis, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi

    Published 2020-06-01
    Get full text
    Article
  7. 7
    A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells

    A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells by Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi

    Published 2023-04-01
    Get full text
    Article

Search Tools: